摘要
目的 应用联苯双酯治疗慢性乙型肝炎 ,观测停药方法及适当指标对丙氨酸转氨酶 ( AL T)反跳的影响。方法 对 15 1例经联苯双酯治疗满 3个月、AL T恢复正常的慢性乙型肝炎患者进行观察 ,其中 91例天冬氨酸转氨酶( AST)恢复正常。停药方式包括一次性停药 ;逐渐减量至停药。两组均于开始治疗一年后复查肝功能。结果 肝功能复查提示 :15 1例患者 AL T反跳率为 2 9.8% ( 4 5 / 15 1) ,一次性停药组与逐渐减量停药组反跳率分别为 2 8.0 % ( 2 1/75 )和 3 1.6% ( 2 4 / 76) ,两组相比无显著差异 ( P>0 .0 5 )。进一步分析表明 :91例 AST恢复正常者 ,AL T反跳率为6.6% ( 6/ 91) ;AST异常 76例 ,AL T反跳率为 66.7% ( 4 0 / 60 )。AST恢复正常组显著低于异常组 ( P<0 .0 1)。结论 应用联苯双酯治疗慢性乙型肝炎 ,当 AL T恢复正常后 ,是否停药 ,何时停药 ,尚需观察 AST是否恢复正常 ,初步认为 AST恢复正常可作为联苯双酯停药的重要指标 。
Objectives:To reveal the effection about withdrawal index and methods of biphenyldicarboxylate in chronic hepatitis on the rebound rate of alanine transaminase(ALT).Subjects and Methods:In 151 patients of chronic hepatitis have been treated by biphenyldicarboxylate for three months,whose alanine transaminase(ALT)returned to normal,there were 91 patientss aspartate amina transferase(AST)returned to normal.The way of suspension included stopping biphenyldicarboxylate immediately and reducing dose gradually to stop.All patients were examined liver function after they had been treated by biphenyldicarboxylate for one year.Results:The rebound rate of ALT is 29 8%(45/151)in all patients.The group of stopping immediately is 28 0%(21/75)and the group of reducing dose gradually to stop is 31 6%(24/73).There is no significant difference between the two groups(P>0 05).We found other questions by researching further.The rebound rate of the AST normal patients is 6 6%(6/91)and AST abnormal patients is 66 7%(40/60).The AST normal group is significantly lower than the AST abnormal group(P<0 01).Conclusions:When stopping biphenyldicarboxylate after ALT returns to normal in chronic hepatitis patients,its important that AST returns to normal.The conclusion suggested that AST returning to normal can be regarded as the important index on suspension of biphenyldicarboxylate.
出处
《福建医药杂志》
CAS
1999年第5期8-9,共2页
Fujian Medical Journal
关键词
慢性
乙型肝炎
联苯双酯
ACT
AST
停药
反跳
Chronic hepatitis Biphenyldicarboxylate Alanine transaminase(ALT) Aspartate amina transferase(AST)
